Skip to main content
XORTX Therapeutics Inc. logo

XORTX Therapeutics Inc. — Investor Relations & Filings

Ticker · XRTX ISIN · CA98420Q2071 LEI · 254900RAT3XZPF9F9350 US Manufacturing
Open in API
Filings indexed 263 across all filing types
Latest filing 2025-10-27 Major Shareholding Noti…
Country CA Canada
Listing US XRTX

About XORTX Therapeutics Inc.

https://www.xortx.com/

XORTX Therapeutics Inc. is a late-stage clinical biopharmaceutical company that develops and commercializes therapies for diseases associated with aberrant purine metabolism and high serum uric acid. The company's pipeline focuses on progressive kidney diseases, including Autosomal Dominant Polycystic Kidney Disease (ADPKD), Type 2 Diabetic Nephropathy (T2DN), and Acute Kidney Injury (AKI), as well as gout. Its lead program, XRx-008, is in development for the treatment of ADPKD.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2025
Major Shareholding Notification
2025-10-27 English
FORM 6-K
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, XORTX Therapeutics Inc., with the SEC. It includes an exhibit index referencing a press release and several agreements related to securities purchase and placement agency. The content indicates updates on financing activities, such as placement agency and securities purchase agreements, which are typical for capital raising or financing updates. The document length is short (1968 characters) and does not contain detailed financial statements or comprehensive report data, but rather references agreements and a press release related to financing. Therefore, the document is best classified as a Capital/Financing Update (CAP).
2025-10-22 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a securities offering by XORTX Therapeutics Inc. It details the terms of the offering of common shares and pre-funded warrants, pricing, placement agent fees, and other offering-related information. The document is a formal disclosure related to capital raising activities and does not contain financial statements or earnings data. It is not an annual or quarterly report, audit report, or earnings release. It is clearly a capital/financing update describing a securities offering and related terms. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2025-10-22 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes a press release as an exhibit but does not contain detailed financial statements or substantive financial data. The document length is short (1231 characters), and it primarily serves as a regulatory announcement of a press release rather than a full financial report. According to the rules, such filings are classified as Regulatory Filings (RNS) because they do not contain the full report or detailed financial data but are regulatory announcements or disclosures.
2025-10-21 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes a signature page and references an attached press release (Exhibit 99.1). The document length is short (1232 characters) and primarily serves as a notification of the press release filing rather than containing substantive financial data or detailed report content. There is no indication of full financial statements or detailed analysis. According to the rules, such filings that serve as regulatory announcements or certifications without substantive financial data should be classified as Regulatory Filings (RNS).
2025-10-21 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC under the Securities Exchange Act of 1934. It is dated October 20, 2025, and includes a press release as Exhibit 99.1. The document length is only 1231 characters, indicating it is a brief filing rather than a full report. Form 6-K filings typically serve as regulatory filings to disclose material information between annual reports. There is no detailed financial data or comprehensive report content present. Therefore, this document fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other categories and includes Form 6-K filings.
2025-10-20 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.